Skip to Content

Notice

You may be interested in this older document that published on 06/14/2024 with action 'Notice of availability.'
View Document

Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Reopening the Comment Period

A Notice by the Food and Drug Administration on 08/08/2024

  • PDF
  • Document Details
  • Document Dates
  • Table of Contents
  • Related Documents
  • Public Comments
  • Regulations.gov Data
  • Sharing
  • Print
  • Document Statistics
  • Other Formats
  • Public Inspection
Published Document: 2024-17645 (89 FR 64929)

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings

Document headings vary by document type but may contain the following:

  1. the agency or agencies that issued and signed a document
  2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  3. the agency docket number / agency internal file number
  4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

See the Document Drafting Handbook for more details.

Department of Health and Human Services
Food and Drug Administration
  1. [Docket No. FDA-2024-N-2422]

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice of availability; reopening the comment period.

( printed page 64930)

SUMMARY:

The Food and Drug Administration (FDA, the Agency, or we) is reopening the comment period for the proposed administrative order (proposed order) entitled “Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use”, announced in the Federal Register of June 14, 2024. We are taking this action due to technical difficulties with the OTC Monographs@FDA portal. Because comments cannot be submitted to the OTC Monographs@FDA portal at this time, submit comments on proposed order (OTC000035) to the Federal eRulemaking portal (Docket No. FDA-2024-N-2422).

DATES:

FDA is reopening the comment period on proposed order (OTC000035) announced in the Federal Register of June 14, 2024 (89 FR 50593). Electronic comments or written comments must be submitted by September 27, 2024.

ADDRESSES:

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of September 27, 2024. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

  • Federal eRulemaking Portal: https://www.regulations.gov. Other than using the Federal eRulemaking Portal to submit comments (instead of the OTC Monographs@FDA portal), follow the instructions for submitting comments on the proposed order (OTC000035) available in the OTCMonographs@FDA portal at https://dps.fda.gov/​omuf.

FOR FURTHER INFORMATION CONTACT:

Helen Lee, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-0138.

SUPPLEMENTARY INFORMATION:

In the Federal Register of June 14, 2024 (89 FR 50593), FDA announced the availability of proposed order (OTC000035) entitled “Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use.” The proposed administrative order (proposed order), if finalized, will amend the requirements for internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter (OTC) human use, as currently described in Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (OTC Monograph M013).[1]

Interested persons were originally given until July 29, 2024, to comment on the proposed order (OTC000035) via the OTC Monographs@FDA portal. However, as of June 14, 2024, technical difficulties prevented the electronic submission of comments through the OTC Monographs@FDA portal. Therefore, we are reopening the comment period for the proposed order (OTC000035) and are instead accepting comments through the Federal eRulemaking Portal. Accordingly, submit comments on the proposed order (OTC000035) electronically using Docket No. FDA-2024-N-2422 in the Federal eRulemaking Portal at https://www.regulations.gov. The reopened comment period will close on September 27, 2024.

The proposed order (OTC000035) remains available in the OTC Monographs@FDA portal at https://dps.fda.gov/​omuf. Other than using the Federal eRulemaking Portal to submit comments (instead of the OTC Monographs@FDA portal), follow the instructions for submitting comments on the proposed order (OTC000035) available in the OTC Monographs@FDA portal at https://dps.fda.gov/​omuf. The proposed order contains general instructions for commenting, which otherwise remain applicable.

Dated: August 5, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.

Footnotes

1.  OTC Monograph M013 is currently set forth in the Final Administrative Order OTC000027. We note that at 89 FR 50593 at 50594, the notice of availability for the proposed order to amend OTC Monograph M013 erroneously referred to “Final Administrative Order OTC000027” as “Final Administrative Order OTC000035.”

Back to Citation

[FR Doc. 2024-17645 Filed 8-7-24; 8:45 am]

BILLING CODE 4164-01-P

Published Document: 2024-17645 (89 FR 64929)